Aiforia Technologies Plc, Press Release, March 6, 2024 at 09:00 a.m. EET
Aiforia Technologies Plc announces the release of Aiforia® Studies, a software module that offers AI-assisted image analysis workflow within the framework of Good Laboratory Practices (GLP). Aiforia® Studies is designed especially for pharmaceutical companies and contract research organizations engaged in non-clinical histology studies that need to adhere to GLP guidelines, although its application is not restricted to such studies.
“Toxicopathologic evaluations in the drug development processes are often conducted within the framework of GLP. Complemented by the new Aiforia® Studies module, Aiforia’s preclinical offering now enables pathologists and scientists to create and test artificial intelligence (AI) models, perform and evaluate cutting-edge AI-assisted image analysis, and export and store immutable study data using the Aiforia platform also within the strict framework of GLP,” says Jukka Tapaninen, CEO of Aiforia.
Certified Adviser
UB Securities Ltd, tel. +358 9 25 380 225
About Aiforia
Aiforia equips pathologists and scientists in preclinical and clinical labs with powerful deep-learning artificial intelligence software for translating images into discoveries, decisions, and diagnoses. The cloud-based Aiforia products and services aim to escalate the efficiency and precision of medical image analysis beyond current capabilities across various fields, from oncology to neuroscience and more. Find out more: www.aiforia.com
Back to all blog posts
